NCT03579966View on ClinicalTrials.gov

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

PHASE3TerminatedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

June 11, 2018

Primary Completion Date

August 5, 2022

Study Completion Date

August 5, 2022

Conditions
Myasthenia Gravis, MuSKAChR Myasthenia Gravis
Interventions
DRUG

Amifampridine Phosphate

tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day

Trial Locations (3)

19104

Univerity of Pennsylvania, Philadelphia

44195

Cleveland Clinic, Cleveland

11-201332

Department of Neuroimmunology and Neuromuscular Diseases Carlo Besta Neurological Institute Via Celoria, Milan

Sponsors
All Listed Sponsors
lead

Catalyst Pharmaceuticals, Inc.

INDUSTRY

NCT03579966 - Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) | Biotech Hunter | Biotech Hunter